| Literature DB >> 24841385 |
Robin R L Simons1, Paul Gale2, Verity Horigan3, Emma L Snary4, Andrew C Breed5.
Abstract
Bat-borne viruses can pose a serious threat to human health, with examples including Nipah virus (NiV) in Bangladesh and Malaysia, and Marburg virus (MARV) in Africa. To date, significant human outbreaks of such viruses have not been reported in the European Union (EU). However, EU countries have strong historical links with many of the countries where NiV and MARV are present and a corresponding high volume of commercial trade and human travel, which poses a potential risk of introduction of these viruses into the EU. In assessing the risks of introduction of these bat-borne zoonotic viruses to the EU, it is important to consider the location and range of bat species known to be susceptible to infection, together with the virus prevalence, seasonality of viral pulses, duration of infection and titre of virus in different bat tissues. In this paper, we review the current scientific knowledge of all these factors, in relation to the introduction of NiV and MARV into the EU.Entities:
Mesh:
Year: 2014 PMID: 24841385 PMCID: PMC4036546 DOI: 10.3390/v6052084
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Bangladesh districts reporting human Nipah virus (NiV) incidents (coloured in red) by year, based on available data [40,41].
Summary of outbreaks in humans and results of testing for NiV in bats.
| Location | Human outbreaks | Results of testing for NiV in bats | Bat species tested | |
|---|---|---|---|---|
| [ | Antibodies | [ | ||
| [ | Antibodies | [ | ||
| [ | Antibodies, Virus isolation | [ | ||
| [ | - | - | ||
| - | RNA, antibodies | [ | ||
| - | Antibodies | [ | ||
| - | Antibodies | [ | ||
| - | Antibodies, virus isolation | [ | ||
| - | Antibodies | [ | ||
| - | Antibodies | [ | ||
| RNA | [ | |||
| - | Antibodies | [ | ||
| Antibodies | [ | |||
| - | Antibodies | [ | ||
Summary of outbreaks in humans and results of testing for Marburg virus (MARV) in bats.
| Location | Human outbreaks | Results of testing for MARV in bats | Bat species tested | |
|---|---|---|---|---|
| [ | - | - | ||
| [ | RNA, antibodies | [ | ||
| [ | RNA | [ | ||
| [ | - | - | ||
| [ | RNA | [ | ||
| - | RNA | [ | ||
* Human case was identified on return to South Africa, but initial infection was thought to be in Zimbabwe.
Figure 2Maps showing countries with reported evidence of human and/or bat infection and countries where bat species associated with infection are present, for NiV (top) and MARV (bottom).
Figure 3Percentage contribution of 2012 EU member states (MS) total passengers on board international extra-EU air passenger transport, between NiV (left) and MARV (right) regions, identified in Figure 2 for 2012. Data from Eurostat (International extra-EU air passenger transport by reporting country and partner world regions and countries [avia_paexcc]) [105].
Figure 4Percentage contribution of 2010 EU MS fruit and pig product trade from NiV (left) and MARV (right) regions, identified in Figure 2. Trade data from Faostat [112].